JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2018, 67(1):14-24 | DOI: 10.36290/csf.2018.002

Liberalization and integration of drug distribution in the EU 28 and Norway

Jaroslav Písek*, Kamil Pícha
Jihočeská univerzita v Českých Budějovicích, Ekonomická fakulta, České Budějovice

The pharmaceutical distribution system in Europe is undergoing a long-term change. Wholesale companies join together to form both horizontally and vertically integrated structures. Pharmacies, formerly owned almost exclusively by pharmacists, are becoming part of the chain thanks to the liberalization of operating conditions. Chains are expanding successfully due to economies of scale and purchasing power for negotiation with suppliers. Independent pharmacies are becoming part of virtual chains to better compete with chains. An assortment previously reserved to pharmacies is also marketed in food stores or gas pumps due to legislative changes. E-pharmacies and e-shops compete in the area of over-the-counter pharmaceuticals and the complementary range of pharmacies. The paper describes systems of pharmaceutical distribution and their specifics in individual EU countries and Norway. In eight EU countries, the legislative framework does not allow the formation of pharmacy chains. More than 50% of public pharmacies are integrated into chains in six member states. A question remains concerning the influence of these different approaches to market regulation and thus different functioning of the market on the availability of pharmaceuticals for customers and also on the total costs of the pharmaceutical distribution system.

Keywords: pharmaceutical distribution; community pharmacy; EU28; liberalization; integration

Received: November 21, 2017; Accepted: January 9, 2018; Published: January 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Písek J, Pícha K. Liberalization and integration of drug distribution in the EU 28 and Norway. Čes. slov. farm. 2018;67(1):14-24. doi: 10.36290/csf.2018.002.
Download citation

References

  1. Kanavos P., Wouters O. J. Competition issues in the distribution of pharmaceuticals. In: OECD Global Forum on Competition 2014.
  2. Pharmine. Country profiles. https://www.pharmine.org/country-profiles (11. 11. 2017).
  3. European Pharmacist Forum. Our countries. http://www.europeanpharmacistsforum.com/our-countries (11. 11. 2017).
  4. DICE Database. Distribution Mark-ups and Value-added Tax (VAT) for Pharmaceuticals, 2007. ifo Institute, Mnichov, Německo. http://www.cesifo-group.de/DICE/fb/nsJPtk4b (11. 11. 2017).
  5. Vogler S. Liberalization in the pharmacy sector. In: OECD Global Forum on Competition 2014.
  6. James Dudley Management International Players Driving European Pharmacy. Newsletter December 2015. http://james-dudley.co.uk
  7. Phoenix Group Annual report 2016/2017. https://www.phoenixgroup.eu
  8. Walgreens Boots Alliance Annual report 2016. http://investor.walgreensbootsalliance.com
  9. Celesio Annual report 2017. http://www.mckesson.eu/mck-en/investors
  10. Penta Investments A good year for the Penta investment group. Press release April 26, 2017. http://www.pentainvestments.com/en/
  11. Eurostat. Population on 1 January, 2017. http://ec.europa.eu/eurostat
  12. Algemene Pharmaceutische Bond De apotheek. http://www.apb.be (11. 11. 2017).
  13. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Country reports. http://whocc.goeg.at/Publications/ (11. 11. 2017).
  14. Multipharma Welkom bij Multipharma. https://www.multipharma.be (11. 11. 2017).
  15. Senato della Repubblica Pharmacy chain overview 2014. https://www.senato.it (15. 9. 2017).
  16. Groupement International de la Répartition Pharmaceutique Wholesalers' directory. http://www.girp.eu/wholesalers-directory (19. 8. 2017).
  17. Kanavos P., Schurer, W., Vogler, S. The pharmaceutical distribution chain in the European Union: structure and impact on pharmaceutical prices. Evropská komise 2011. http://eprints.lse.ac.uk/51051/
  18. Danish Medicines Agency Pharmacies in Denmark. http://laegemiddelstyrelsen.dk (16. 8. 2017).
  19. Dočkal M. Estonsko reguluje provoz lékáren. APATYKÁŘ® 13. 7. 2017. http://lekarenstvi.apatykar.info/lekarenstvi-ve-svete/clanek-3234/
  20. The Association of Finnish Pharmacies Annual review 2016. http://www.apteekkariliitto.fi/en/annual-reviews.html
  21. Team Finland A robotics expert is automating pharmacies. 9. 6. 2016. http://team.finland.fi/en
  22. European Pharmacist Forum Our countries. http://www.europeanpharmacistsforum.com (14. 11. 2017).
  23. Ordre National Des Pharmaciens Rapport d'activitér. http://www.ordre.pharmacien.fr (27. 6. 2017).
  24. Hrvatska ljekarnička komora Pharmacy in Croatia. http://www.hljk.hr (17. 8. 2017).
  25. Gradska Ljekarna Zagreb Kontakt podaci ljekarne. http://www.gljz.hr (19. 8. 2017).
  26. The Pharmaceutical Society of Ireland Statistics Pharmacies August 2017. http://www.thepsi.ie/gns/Registration/public-registers/Statistics.aspx
  27. Dočkal M. Lékárenský monopol v Itálii končí. APATYKÁŘ® 3. 8. 2017. http://lekarenstvi.apatykar.info/lekarenstvi-ve-svete/clanek-4044/
  28. Ministry of Health Cyprus Kατάλογος Ιδωτικών Φαρμακείων (Pi;αγκύπρι&alpha). http://www.moh.gov.cy (19. 8. 2017).
  29. Le Gouvernement Du Grand-Duché de Luxemburg Etudes & Métiers: Professions médicales (édition 2015/2016). http://www.sante.public.lu/fr/publications/index.php
  30. Government of Malta Medicines Authority. http://www.medicinesauthority.gov.mt/licensed-pharmaceutical-activities (19. 8. 2017).
  31. ABDA German pharmacies: Figures Data Facts 2017. https://www.abda.de
  32. Arentz O., Recker C., Vuong V. A., Wambach A. Entry in German Pharmacy Market. Otto Wolff Institut. Draft version March 2016. http://www.otto-wolff-institut.de/Publikationen/DiskussionPapers/
  33. Vogler S., Arts D., Habl C. Community Pharmacy in Europe. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, February 2006. http://whocc.goeg.at/Publications/BooksReports
  34. Magowska A. Pharmacy chains versus private pharmacies in Poland, 1989-2015. DEBATER A EUROPA. N.14 janeiro/junho 2016 - Semestral. http://www.europe-direct-aveiro.aeva.eu/debatereuropa/ Go to original source...
  35. Österreichische Apothekerkammer Apotheke in zahlen 2017. http://www.apotheker.or.at
  36. WHO ROMANIA Pharmaceutical Sector Analysis. http://apps.who.int/medicinedocs/documents/s16762e/s16762e.pdf (22. 8. 2017).
  37. Dočkal M. Klasické lékárenství v Řecku končí. APATYKÁŘ® 31. 3. 2014. http://lekarenstvi.apatykar.info/lekarenstvi-ve-svete/clanek-2755/
  38. Vozikis A., Stavropoulou L., Patrinos G.P. Community Pharmacists' Strategies in Greece. Health 2015; 7, 1560-1577. Go to original source...
  39. Szalayová A., Skybová K., Kandilaki D., Szalay T. Analýza lekárenského trhu na Slovensku a v Českej republike. Health Policy Institute, Bratislava, září 2014. http://www.hpi.sk/2014/09/analyza-lekarenskeho-trhu/
  40. Lekarniška zbornica Slovenije Mreža lekarn. http://www.lzs.si (22. 8. 2017).
  41. Läkemedelsverket The Swedish pharmacy market. https://lakemedelsverket.se (24. 8. 2017).
  42. Apoteket Handla på apoteket.se. https://www.apoteket.se/kundservice/handla-pa-apoteket/ (24. 8. 2017).
  43. General Pharmaceutical Council Pharmacy Register. https://www.pharmacyregulation.org/registers (29. 6. 2017).
  44. Apotekforeningen Statistikk for 2016: Apotek- og legemiddelstatistikk.http://www.apotek.no/fakta-og-ressurser/statistikk-for-2016




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.